Course of Care for Hepatitis C in Users of Psycho-active Substances According to the Addictological System of Care and Place of the Test and Treat Strategy

Course of Care for Hepatitis C in Users of Psycho-active Substances According to the Addictological System of Care and Place of the Test and Treat Strategy

Coraline Biehler ¹, Frédéric Chaffraix ^2,3, Fiorant Di Nino ^1,2, Camille Brand ¹, Flavie Oster ¹, Samira Fafi-Kremer ⁴, Gauthier Waeckerle ¹, Michel Hasselmann ¹, Michel Doffoël ^2,3

¹ Association Ithaque, 12 rue Kuhn, 67000 STRASBOURG, France; ² Association de Lutte contre les Maladies du Foie (ALMAF), 23 rue de la 1ère Armée, 67000 STRASBOURG, France; ³ Service Expert de Lutte contre les Hépatites Virales d’Alsace (SELHVA), Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil- Pole Hépato Digestif, 1 place de l’hôpital – BP426, 67091 STRASBOURG Cedex, France; ⁴ Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil, 1 place de l’hôpital – BP426, 67091 STRASBOURG Cedex, France

Aim: The treatment of addiction is well structured in France, with different care and prevention services available, such as addiction treatment and prevention centers, the network of medical microstructures centred on general practitioners, and lower risk consumption rooms. The objectives of our study were to compare the courses of care for hepatitis C provided within one addictology center offering all three of these services, as well as to clarify the role and factors associated with the test and treat strategy.

Methods: 573 users were included prospectively from all three of the above-mentioned services: 168 from the addiction treatment and prevention center, 291 from the network of medical microstructures and 114 from the lower risk consumption room. They were consumers of one or several psycho-active substances (illegal substances, alcohol, tobacco). The different hepatitis C courses of care were compared between the three services. The test and treat strategy was evaluated in comparison with conventional strategy in all the users.

Results: The users were characterized as being predominantly male (65.4%), with high occurrence of polydrug use (61.2%) and low socioeconomic status (complementary health solidarity 43.8%, precarious housing or homelessness 23.9%, living alone 47.1% and lack of paid employment 72.9%). The course of care for hepatitis C did not differ significantly between the three services: screening performed for 90% with HCV RNA detected in 100% of users, access to treatment varied from 61 to 100%; hepatitis C was cured in all users. The test and treat strategy was used in the majority of cases, particularly those treated at lower risk consumption room (93.8%). This strategy was associated with type of consumption and low socioeconomic status (p <0.001). It also correlated with easier and faster access to antiviral treatment (80.6%) compared to the conventional strategy (45.4%, p <0.05).

Conclusions: This study confirms the benefit of using the test and treat strategy for fast treatment of hepatitis C in psycho-active drug users leading to consistent cure and the emergence of a new strategy named “test and cure”.

Keywords: hepatitis C, use of psycho-active substances, course of care, test and treat strategy

Free Full-text PDF

How to cite this article:
Coraline Biehler, Frédéric Chaffraix, Fiorant Di Nino, Camille Brand , Flavie Oster, Samira Fafi-Kremer, Gauthier Waeckerle, Michel Hasselmann, Michel Doffoël.Course of Care for Hepatitis C in Users of Psycho-active Substances According to the Addictological System of Care and Place of the Test and Treat Strategy.Open Journal of Gastroenterology and Hepatology, 2022, 5:63. DOI: 10.28933/ojgh-2022-09-0105cb

References:

1. Stratégie nationale de santé 2018-2022. https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/strategie-nationale-de-sante/article/la-strategie-nationale-de-sante-2018-2022 consulté le 29/04/22
2. Ministère des Solidarités et de la Santé. Instruction N° DGOS/PF2/DGS/SP2/DSS/1C/2017/246 du 3 août 2017 relative à l’élargissement de la prise en charge par l’assurance maladie du traitement de l’hépatite C par les nouveaux agents antiviraux d’action directe (AAD) à tous les stades de fibrose hépatique pour les indications prévues par l’autorisation de mise sur le marché et à la limitation de la tenue d’une réunion de concertation pluridisciplinaire pour les initiations de traitement à des situations particulières listées. 2017. p. 9. Ministère des affaires sociales et de la Santé. https://solidarites-sante.gouv.fr/fichiers/bo/2017/17-08/ste_20170008_0000_0046.pdf
3. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C. Final update of the series. J Hepatol 2020; 73:1170–218. https://doi.org/10.1016/j.jhep.2020.08.018
4. Pol S, Fouad F, Lemaitre M, Rodriguez I, Lada O, Rabiega P, et al. Impact of extending direct antiviral agents (DAA) availability in France : an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS). The Lancet Regional Health-Europe 2022 ; 13 :100281. https://doi.org/10.1016/j.lanepe.2021.100281
5. Bajis S, Grebely J, Hajarizadeh B, Applegate T, Marshall AD, Ellen Harrod M et al. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post universal acess to direct-acting antiviral treatment in Australia : the LiveRLife study. J Viral Hepat 2020 ; 27 :281-93. https://doi.org/10.1111/jvh.13233
6. Haute Autorité de Santé. Place des tests rapides d’orientation diagnostique (TROD) dans la stratégie de dépistage de l’hépatite C. Saint Denis : HAS ; 2014 : 106p. https://www.has-sante.fr/jcms/c_1615995/fr/place-des-tests-rapides-d-orientation-diagnostique-trod-dans-la-strategie-de-depistage-de-l-hepatite-c
7. Grebely J, Lamoury FMJ, Hajarizadeh B, Mowat Y, Marshall AD, Bajis S, et al. Evaluation of the Xpert HCV Viral Load point-ofcare assay from venepuncture-collected and finger-stick capillary whole-blood samples : a cohort study. The Lancet Gastro Hepatol 2017 ; 2 : 514-20. https://doi.org/10.1016/s2468-1253(17)30075-4
8. Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol 2016; 13:402–11
9. Haute Autorité de Santé. Avis de la HAS sur le protocole de coopération : « Mesure de l’élastométrie du foie avec l’appareil de mesure FibroScan en lieu et place d’un médecin ». https://www.has-sante.fr/jcms/c_1615917/fr/avis-de-la-has-sur-le-protocole-de-cooperation-mesure-de-l-elastometrie-du-foie-avec-l-appareil-de-mesure-fibroscan-en-lieu-et-place-d-un-medecin
10. Association Française pour l’Etude du Foie. Recommandations AFEF pour l’élimination de l’infection par le virus de l’hépatite C en France, mars 2018. https://afef.asso.fr/wp-content/uploads/2018/06/VF-INTERACTIF-RECO-VHC-AFEF-v2103.pdf
11. Association Française pour l’Etude du Foie. Recommandations pour le diagnostic et le suivi non-invasif des maladies chroniques du foie, juillet 2020. https://afef.asso.fr/wp-content/uploads/2020/07/DNI-VERSION-FINALE-RECO-2020.pdf
12. Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J et al. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy 2015; 26:1028-38. https://doi.org/10.1016/j.drugpo.2015.07.005
13. Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, et al. (2016) Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol 14: 1035-1043. https://doi.org/10.1016/j.cgh.2016.03.040
14. Younossi ZM, Bacon BR, Dieterich DT, Flamm SL, Kowdley K, et al. (2016) Disparate access to treatment regimens in chronic hepatitis C patients; data from the TRIO network. J Viral Hepat 23: 447-454. https://doi.org/10.1111/jvh.12506
15. Zuckerman A, Douglas A, Nwosu S, Choi L, Chastain C (2018) Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era. PLOS ONE 13: e0199174. https://doi.org/10.1371/journal.pone.0199174
16. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9 https://doi.org/10.1016/S0168-8278(00)00097-0
17. Michel D, Fiorant DN, Frédéric C, Anais L, Laurence L (2019) Impact of Direct-acting Antivirals on Hepatitis C Cascade of Care among People who Inject Drugs. J Antivir Antiretrovir. 11:179. https://www.longdom.org/open-access/impact-of-directacting-antivirals-on-hepatitis-c-cascade-of-care-among-people-who-inject-drugs-18146.html
18. Di Nino F, Imbs JL, Melenotte GH, le réseau RMS, Doffoel M. Screening and treatment of hepatitis C in drug users through a network of medical microstructures in Alsace, France, 2006-2007. Bull Epidémiol Hebd 2009; 37 : 400-3. http://beh.santepubliquefrance.fr/beh/2009/37/index.htm
19. Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson JM, et al. Prevalence of hepatitis B and C virus infection in France in 2004 : social factors are important predictors after adjusting for known risk factors. J Med Virol 2010 ; 82 : 546-55. https://doi.org/10.1002/jmv.21734
20. Organisation de la prise en charge thérapeutique et du suivi des personnes usagères de drogues infectées par le virus de l’hépatite C. In Prise en charge thérapeutique et suivi de l’ensemble des personnes infectées par le virus de l’hépatite C. Rapport de recommandations 2016. EDP Sciences, Montrouge, France, 2016, p 13-30. https://www.vie-publique.fr/rapport/36046-prise-en-charge-therapeutique-et-suivi-de-lensemble-des-personnes-infec
21. La réduction des risques associés à la consommation d’alcool. Mission interministérielle de lutte contre les drogues et les conduites addictives (Mildeca), septembre 2021. https://www.drogues.gouv.fr/comprendre/ce-qu-il-faut-savoir-sur/reduction-risques-associes-consommation-dalcool-principes-de-lintervention
22. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. (2007) Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus; evidence from the Amsterdam cohort studies among drug users. Addiction 102:1454-1462. https://doi.org/10.1111/j.1360-0443.2007.01912.x
23. Lamoury F, Bajis S, Hajarizadeh B, Marshall A, Martinello M, Ivanova E et al. Evaluation of the Xpert HCV viral load finger-stickpoint-of-care assay. J Infect Dis 2018; 217: 1889-96. https://doi.org/10.1093/infdis/jiy114
24. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960–74. https://doi.org/10.1053/j.gastro.2008.01.034
25. Foucher J, Reiller B, Jullien V, Léal F, di Cesare ES, Merrouche W, et al. FibroScan used in street-based outreach for drug users is useful for hepatitis C virus screening and management: a prospective study. J Viral Hepat 2009; 16:121–31.
26. Wiesmann F Braun P. Significance of HCV RNA monitoring in the era of new potent therapies. Expert Rev Anti Infect Ther 2016; 14: 837-44 https://doi.org/10.1080/14787210.2016.1214355
27. Hezode C. Pan-genotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions. J Viral Hepat 2017; 24: 92-101 https://doi.org/10.1111/jvh.12635
28. Maasoumy B, Vermehren J. Diagnostics in hepatitis C: the end of response-guided therapy? J Hepatol 2016; 65 (1 Suppl): S67-81 https://doi.org/10.1016/j.jhep.2016.07.023
29. MSF Access Campaign. Hepatitis C. Not even close. https://www.msfaccess org/hep-c-not-even-close
30. Juanbeltz R, Goni Esarte S, Uriz-Otano JI, Echeverria AM, Elizaldo I, Zozava JM et al. Safety of oral direct acting anti-viral regimens for chronic hepatitis C in real life conditions. Postgrad Med 2017;129: 476-83. https://doi.org/10.1080/00325481.2017.1311197
31. Applegate TL, Fajardo E, Sacks JA. Hepatitis C virus diagnosis and the holy grail. Infect Dis Clin N Am 2018; 32: 425-45. https://doi.org/10.1016/j.idc.2018.02.010
32. Di Nino F, Oster F, Waeckerle G, Bader D, Chaffraix F, Fafi-Kremer S, Doffoel M. Vers une stratégie « test and cure » chez les usagers de drogues de la salle de consommation à moindre risque. Association Française pour l’Etude du Foie, Lyon 2018, Abst P025. https://afef.asso.fr/wp-content/uploads/2018/10/CA- AFEF-2018.pdf